HomeIgnyta Announces Phase 1 Clinical Trial Data for Entrectinib

Ignyta Announces Phase 1 Clinical Trial Data for Entrectinib

Nerviano, 01.06.2015
  • Well tolerated, with no drug-related serious adverse events
  • Recommended Phase 2 dose determined
  • 91% response rate in patients meeting expected Phase 2 eligibility criteria

More info on Ignyta website, at the following link https://ignyta.com/investors/press-release-article/915636/